Zydus gets USFDA approval for Apixaban

On Tuesday, Zydus Lifesciences said that the US health agency has given the company permission to distribute a generic drug for the prevention and treatment of blood clots. 

According to a regulatory filing, the business has been given permission by the US Food and Drug Administration (USFDA) to market Apixaban pills in dosages of 2.5 and 5 mg.

Apixaban prevents specific blood clotting agents from working. It is used to reduce the risk of a blood clot or stroke in persons with atrial fibrillation, a heart rhythm problem.

Moreover, it is used to lessen the possibility of blood clots developing in the lungs and legs of patients who have recently undergone hip or knee replacement surgery.

The Zydus group’s formulation manufacturing facility in Moraiya, Ahmedabad, will produce the medication.

Apixaban tablets generated yearly sales of USD 18,876 million in the US, according to IQVIA MAT data from December 2022.

For feedback and suggestions, write to us at editorial@iifl.com